---
$id: https://graph.org.ai/products/commodity/51142529
$type: Product
source: UNSPSC
code: "51142529"
title: "Lazabemide"
class: "51142500"
classTitle: "Antiparkinson drugs"
family: "51140000"
familyTitle: "Central nervous system drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Lazabemide

**UNSPSC Code**: 51142529
**Class**: [Antiparkinson drugs](Antiparkinson drugs.mdx)
**Family**: [Central nervous system drugs](../Central nervous system drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoamine oxidase inhibitor with the molecular formula C8H10ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 420HD787N9, chemically known as 2-pyridinecarboxamide, n-(2-aminoethyl)-5-chloro- but generally known as lazabemide, which bears US NIH Compound Identifier 71307. European Medicines Agency schedules Lazabemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08418MIG. The term LAZABEMIDE is an International Non-Proprietary Name. LAZABEMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lazabemide under HS 29333999 and SITC 51574. As of Q4 2014, LAZABEMIDE remains the US FDA Preferred Term for this commodity. Lazabemide bears US NLM identifiers UMLS ID C0209106 and NCI Concept Code C80964. SMILES: CLC1CCC(NC1)C(=O)NCCN.

